The researchers believe they can develop hereditary screening test which could inform doctors which prostate cancer patient require belligerent treatment than other. The earlier study trails suggested that males with greater levels of CCP-cell cycle progression gene have the most lethal forms of tumours.
Prostate cancer the most common form of cancer among males around the globe and each year around thirty-seven thousand new cases are diagnosed only in UK. According to estimation by Cancer Research UK, about two third of males with raised levels of PSA- Prostate Specific Antigen will not have prostate cancer.
However, they will undergo anxiety, discomfort and risk of follow up investigations. The research team from Queen Mary, University of London, anticipates their new CCP test along with existing test such as PSA, could be used regularly in the clinic to conquer this problem.
In the study carried out by team led by Prof Jack Cuzick included more than seven hundred males suffering prostate cancer, found that CCP could envisage probable disease upshots. Males with highest CCP genes levels were three times more prone than those with lowest levels of CCP genes, to have deadly form of prostate cancer.
Moreover the patients who have had surgery to remove their prostate, those with the highest levels of CCP genes were seventy percent more prone to have a reappearance of the disease. Their findings have great potential. CCP genes are articulated at higher levels in actively growing cells, added Prof Cuzick.
He added, they could indirectly gauge the rate of growth and intrinsic aggressiveness of the tumour through their test. It is already known that CCP levels can envisage survival for breast, brain and lung cancers. It is really cheering that this could also be useful to prostate cancer, where they desperately need a way to predict how aggressive the disease will be.